JAMA

doi: 10.1001/jama.1996.03530420014007pmid: N/A

doi: 10.1001/jama.1996.03530420013005pmid: N/A

doi: 10.1001/jama.1996.03530420014006pmid: N/A

Southgate, M. Therese

doi: 10.1001/jama.1996.03530420006001pmid: N/A

Lynn, John T.

doi: 10.1001/jama.1996.03530420008002pmid: N/A

doi: 10.1001/jama.1996.03530420009003pmid: N/A

Nora, James J.

doi: 10.1001/jama.1996.03530420012004pmid: N/A

doi: 10.1001/jama.1996.03530420015008pmid: N/A

Stephenson, Joan

doi: 10.1001/jama.1996.03530420017009pmid: N/A

NEW FINDINGS from a long-term, prospective observational study on aging indicate that men and women who take nonsteroidal anti-inflammatory drugs (NSAIDs) and women who receive estrogen replacement therapy have a markedly reduced risk of developing Alzheimer disease. The results, reported at the annual meeting of the American Academy of Neurology, in San Francisco, Calif, confirm suggestions from previous studies that the agents may help prevent the disease or slow its progression. Although the investigators caution that their work shows an association rather than a causal link between these drugs and the disease, they say that hints that these agents may have neuroprotective effects against the devastating illness are promising enough to warrant clinical trials to look for definitive answers. Earlier research suggesting a link between inflammation-fighting drugs and a reduced risk of Alzheimer disease included a 1994 Duke University study of 50 sets of elderly twins. This study found that

Voelker, Rebecca

doi: 10.1001/jama.1996.03530420018010pmid: N/A

A NEW REPORT that recommends restructuring federal AIDS research has reignited a tug-of-war over who should control the purse strings for such research. During a news conference last month in Chicago, Ill, a trio of AIDS experts called on a small group in Congress to restore full spending authority to the Office of AIDS Research (OAR) of the National Institutes of Health (NIH). "The promise of AIDS research is very much at risk because of these debates," said Mathilde Krim, PhD, chair of the American Foundation for AIDS Research (AmFAR). Krim was joined by Mark Harrington, policy director of the New York, NY—based Treatment Action Group, and Steven Wolinsky, MD, associate professor of medicine at the Northwestern University Medical School in Chicago. Harrington and Wolinsky were among the 114 scientists, academics, drug company representatives, and community advocates who conducted a sweeping review of the $1.4 billion NIH AIDS research effort.